Skip to main content
Full access
Letter to the Editor
Published Online: 1 May 1999

Addition of Naltrexone to Fluoxetine in the Treatment of Binge Eating Disorder

Publication: American Journal of Psychiatry
To the Editor: Binge eating disorder is characterized by the presence of recurrent binge eating episodes and the absence of inappropriate compensatory behaviors to avoid weight gain (DSM-IV). Serotonergic agents, e.g., fluoxetine, may be effective to reduce binge frequency and induce weight loss (1). In humans, opiate antagonists, e.g., naltrexone, have proven to have robust short-term effects on food intake and eating behavior, but the value of naltrexone alone for long-term treatment of eating disorders is limited (2).
Ms. A was a 16-year-old girl who was hospitalized because of binge eating disorder with a complete loss of control of food intake and a severe major depressive episode including suicidal ideation and self-harming behavior (cutting herself). At hospitalization, her weight was 57.6 kg. Binges occurred at least once a day, and the amount of calories per day was about 5,000. Given the evidence that fluoxetine may be effective in reducing weight, Ms. A was treated with a regimen of fluoxetine, up to 60 mg/day, cognitive behavioral therapy, and dietary management. After several weeks, the depressive symptoms improved, but episodes of bingeing remained unchanged. Thus, we decided to administer, in addition to the described treatment schedule, the opiate antagonist naltrexone, at a daily dose of 100 mg. Within 14 days, we found a robust reduction in binge frequency and the amount of food consumed by Ms. A and weight loss. After discharge, Ms. A was treated with a regimen of fluoxetine (at 60 mg/day), naltrexone (at 100 mg/day), and psychotherapy. Follow-up data after 1 year showed that Ms. A’s weight (49 kg) had remained stable, and she never reported more than 2 binges/month. No side effects were documented. After 1 year, the daily dose of naltrexone was reduced to 50 mg/day, which was followed within 2 weeks by an increase in binge frequency. When we increased the dose of naltrexone to 100 mg/day, the symptoms disappeared again.
The present study is in line with controlled trials proving the efficacy of fluoxetine in the treatment of adolescent depression (3). Fluoxetine and psychotherapy alone did not reduce weight or binge frequency in Ms. A. The efficacy of naltrexone to reduce binge frequency supports hypotheses that endogenous opioid systems may play a role in binge eating disorder. It is interesting that the binge frequency was only reduced at a higher dose of naltrexone but not at a lower dose, arguing for a dose-dependent effect. The treatment combination of fluoxetine and naltrexone could possibly be a new strategy in the treatment of binge eating disorder in adolescents. Clearly, our findings have to be considered preliminary and must be confirmed in placebo-controlled, double-blind trials.

References

1.
Fluoxetine Bulimia Nervosa Collaborative Study Group: Fluoxetine in the treatment of bulimia nervosa. Arch Gen Psychiatry 1992; 49:139–147
2.
deZwaan M, Mitchell JE: Opiate antagonists and eating behavior in humans: a review. J Clin Pharmacol 1992; 32:1060–1072
3.
Simeon JG, Dinicola VF, Ferguson HB, Copping W: Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14:791–795

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 797
PubMed: 10327921

History

Published online: 1 May 1999
Published in print: May 1999

Authors

Affiliations

ALEXANDER NEUMEISTER, M.D.
CICEK WÖBER-BINGÖL, M.D.
Vienna, Austria

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share